ZBIO — ZENAS BIOPHARMA INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 162 SEC-registered investment managers reported holding ZBIO (ZENAS BIOPHARMA INC) in their latest 13F filings, with a combined reported value of $1.69B across 189.15M shares. That is +10.4% by share count (+16.69M shares) versus the previous quarter, while reported value moved +35.8%. Ownership is concentrated: the five largest holders account for 38.5% of reported value and the top ten for 58.1%.
Compared with the prior quarter, 34 opened new positions, 66 added to existing stakes, 41 trimmed, 29 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of ZENAS BIOPHARMA INC (ZBIO) include Fidelity Management & Research (FMR), SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, ranked by reported 13F value among the 249 institutional holders on this page.
ZBIO is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 107 | 79.23M | $947.71M | -5.2% |
| Q2 2026 | 162 | 189.15M | $1.69B | +10.4% |
| Q1 2026 | 156 | 206.91M | $1.30B | +31.4% |
| Q4 2025 | 132 | 44.20M | $1.59B | +15.1% |
| Q3 2025 | 86 | 36.34M | $799.87M | +2.7% |
| Q2 2025 | 77 | 35.57M | $339.92M | +3.2% |
| Q1 2025 | 70 | 34.00M | $264.54M | +4.9% |
| Q4 2024 | 68 | 33.58M | $270.72M | +4.2% |
Over the 8 quarters shown, institutional share counts increased 136% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q1 2026 (+31.4%).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 9.79M | $264.11M | 0.01% | Add | |
| 3.33M | $89.88M | 0.00% | Add | |
| 3.11M | $83.80M | 0.12% | Hold | |
| 2.93M | $78.90M | 0.02% | Add | |
| 2.39M | $64.41M | 32.82% | Hold | |
| 1.88M | $50.77M | 0.00% | Add | |
| 1.84M | $49.58M | 17.59% | Hold | |
| 1.72M | $46.46M | 0.00% | Add | |
| 31.05M | $39.70M | 1.32% | Reduce | |
| 1.06M | $28.60M | 0.00% | Add | |
| 654.83K | $17.73M | 0.08% | New | |
| 426.74K | $11.51M | 5.01% | Hold | |
| 384.15K | $10.36M | 0.00% | Add | |
| 7.80M | $10.08M | 0.33% | New | |
| 334.06K | $9.01M | 1.15% | Reduce | |
| 331.99K | $8.95M | 0.00% | Add | |
| 309.62K | $8.35M | 0.00% | Add | |
| 252.65K | $6.81M | 0.01% | Add | |
| 233.18K | $6.29M | 2.56% | Reduce | |
| 189.66K | $5.12M | 0.00% | Add | |
| 3.60M | $4.63M | 0.09% | Reduce | |
| 166.85K | $4.50M | 0.01% | Reduce | |
| 119.55K | $3.22M | 0.02% | Reduce | |
| 2.36M | $3.02M | 0.10% | Hold | |
| 111.65K | $3.01M | 0.00% | Add |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
Q1 2026 — 25 funds
Q4 2025 — 25 funds
Q3 2025 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 4.91M | $109.04M | 15.77% | Hold | |
| 4.82M | $107.01M | 0.01% | Add | |
| 3.76M | $83.50M | 25.50% | Hold | |
| 2.73M | $60.69M | 3.33% | Hold | |
| 2.00M | $44.40M | 2.86% | Reduce | |
| 1.89M | $42.02M | 3.78% | Hold | |
| 1.86M | $41.33M | 0.07% | Hold | |
| 1.84M | $40.81M | 24.58% | Hold | |
| 1.56M | $34.70M | 0.56% | Hold | |
| 1.23M | $27.28M | 0.00% | Add | |
| 1.18M | $26.27M | 2.11% | Hold | |
| 1.16M | $25.81M | 0.00% | Add | |
| 857.52K | $19.04M | 0.00% | Reduce | |
| 857.52K | $19.04M | 0.00% | Reduce | |
| 824.67K | $18.31M | 0.34% | Reduce | |
| 779.04K | $17.29M | 10.00% | Hold | |
| 580.68K | $12.89M | 0.77% | Reduce | |
| 470.04K | $10.44M | 0.00% | Add | |
| 377.49K | $8.38M | 0.00% | Add | |
| 374.30K | $8.31M | 0.00% | Reduce | |
| 178.40K | $3.96M | 0.00% | Add | |
| 178.40K | $3.96M | 0.00% | Add | |
| 158.74K | $3.52M | 0.26% | Reduce | |
| 152.03K | $3.37M | 2.08% | Reduce | |
| 145.80K | $3.24M | 0.00% | New |
Q2 2025 — 25 funds
New Positions (Q2 2026)
- GEODE CAPITAL MANAGEMENT, LLC 882.65K sh · $22.41M
- READYSTATE ASSET MANAGEMENT LP 6.50M sh · $7.74M
- Sixth Street Partners Management Company, L.P. 302.08K sh · $7.67M
- ADVENT CAPITAL MANAGEMENT /DE/ 2.36M sh · $2.82M
- Verition Fund Management LLC 72.99K sh · $1.85M
- CSM Advisors, LLC 67.62K sh · $1.72M
- AGF MANAGEMENT LTD 1.20M sh · $1.42M
- LOS ANGELES CAPITAL MANAGEMENT LLC 48.47K sh · $1.23M
- BOOTHBAY FUND MANAGEMENT, LLC 33.28K sh · $844.65K
- DCF Advisers, LLC 28.18K sh · $715.31K
- Y-Intercept (Hong Kong) Ltd 17.33K sh · $439.89K
- Point72 Asset Management 16.14K sh · $409.53K
Fully Exited (vs previous quarter)
- STATE STREET CORP sold 1.47M sh · $28.76M
- HIGHBRIDGE CAPITAL MANAGEMENT LLC sold 20.00M sh · $19.79M
- BRAIDWELL LP sold 13.00M sh · $13.46M
- GREAT POINT PARTNERS LLC sold 524.07K sh · $10.25M
- SEB Asset Management AB sold 163.86K sh · $3.20M
- D. E. Shaw & Co sold 3.00M sh · $3.12M
- D. E. Shaw & Co., Inc. sold 3.00M sh · $3.12M
- Monashee Investment Management LLC sold 150.00K sh · $2.93M
- Calamos Advisors LLC sold 2.50M sh · $2.59M
- Maven Securities LTD sold 1.50M sh · $1.55M
- VOLORIDGE INVESTMENT MANAGEMENT, LLC sold 77.49K sh · $1.51M
- DAFNA Capital Management LLC sold 42.50K sh · $830.88K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Fidelity Management & Research (FMR) | 9.79M | 9.51M | 9.08M | 7.70M | 4.82M | 3.32M | 2.85M | 1.78M | 2.00M |
| BlackRock Inc | 3.33M | 2.69M | 2.04M | 1.77M | 1.23M | 1.10M | 1.01M | 1.01M | — |
| FEDERATED HERMES, INC. | 3.11M | 3.12M | 3.13M | 2.72M | 1.86M | 1.86M | 1.16M | 1.16M | 1.16M |
| Capital International Investors | 2.93M | 2.50M | 2.43M | — | — | — | — | — | — |
| Royalty Pharma Sub-Manager, LLC | 2.39M | 2.39M | 2.39M | 1.26M | — | — | — | — | — |
| STATE STREET CORP | 1.88M | — | 1.47M | 438.29K | 377.49K | 310.24K | 266.20K | 211.51K | — |
| NVP Associates, LLC | 1.84M | 1.84M | 1.84M | 1.84M | 1.84M | 1.84M | 1.84M | 1.84M | 1.84M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.72M | 1.35M | 1.25M | — | — | — | — | — | — |
| Context Capital Management, LLC | 31.05M | 35.80M | 29.10M | — | — | — | — | — | — |
| Geode Capital Management | 1.06M | 882.65K | 655.78K | 588.39K | 470.04K | 373.62K | 357.16K | 348.76K | 24.86K |
| Candriam S.C.A. | 654.83K | — | — | — | — | — | — | — | — |
| NEXTBio Capital Management LP | 426.74K | 426.74K | 426.74K | 321.98K | — | — | — | — | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 384.15K | 304.87K | 251.41K | — | — | — | — | — | — |
| DeepCurrents Investment Group LLC | 7.80M | — | — | — | — | — | — | — | — |
| SILVERARC CAPITAL MANAGEMENT, LLC | 334.06K | 509.79K | 1.14M | — | — | — | — | — | — |
| UBS Group AG | 331.99K | 178.09K | 367.40K | 69.50K | 35.49K | 24.26K | 20.77K | 131.66K | 59 |
| VANGUARD FIDUCIARY TRUST CO | 309.62K | 254.62K | 179.39K | — | — | — | — | — | — |
| BARCLAYS PLC | 252.65K | 115.97K | 29.61K | 34.38K | 22.88K | 27.81K | 16.16K | 23.94K | 15.50K |
| Pivotal bioVenture Partners Investment Advisor LLC | 233.18K | 490.77K | 591.99K | 591.99K | 779.04K | 779.04K | 736.64K | 736.64K | 650.70K |
| Morgan Stanley | 189.66K | 134.98K | 93.40K | 128.34K | 88.73K | 124.30K | 77.91K | 358.21K | 51.05K |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold ZBIO?
As of 2026-Q2, 162 institutional funds reported holding ZBIO (ZENAS BIOPHARMA INC) in SEC 13F filings, with a combined reported value of $1.69B.
How many shares of ZBIO do institutions own?
13F filers reported 189.15M shares of ZBIO, worth $1.69B in aggregate at the end of 2026-Q2.
Is institutional ownership of ZBIO rising or falling?
Share counts moved +10.4% versus the prior quarter — accumulation.
Who are the top institutional holders of ZBIO?
The largest 13F holders are Fidelity Management & Research (FMR), SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, BlackRock Inc; the top 25 are ranked at the top of this page.
Who are the major shareholders of ZENAS BIOPHARMA INC?
The major shareholders of ZENAS BIOPHARMA INC (ZBIO) by reported 13F value are Fidelity Management & Research (FMR), SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, BlackRock Inc, among 249 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.